Retatrutide, a experimental dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is showing promising data in initial patient studies. Current research suggests that retatrutide may offer significant benefits for people with obesity, particularly regarding weight loss and glucose control . F